Symptomatic Intracranial Hemorrhage following Intravenous Thrombolysis for Acute Ischemic Stroke: A Critical Review of Case Definitions

被引:169
作者
Seet, Raymond C. S. [1 ,2 ]
Rabinstein, Alejandro A. [1 ]
机构
[1] Mayo Clin, Dept Neurol, Rochester, MN USA
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
Recombinant tissue plasminogen activator; Ischemic stroke; Symptomatic intracranial hemorrhage; TISSUE-PLASMINOGEN-ACTIVATOR; INTRACEREBRAL HEMORRHAGE; CANADIAN ALTEPLASE; CLINICAL-PRACTICE; H; THERAPY; EXPERIENCE; SAFETY; RISK; CLASSIFICATION;
D O I
10.1159/000339675
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Symptomatic intracranial hemorrhage (SICH) is a devastating complication of intravenous thrombolysis treatment that is associated with high mortality. Clinical trials, stroke registries and cohort studies employ different case definitions to identify stroke patients with SICH following intravenous thrombolysis. We systematically reviewed the reported rates of SICH following intravenous thrombolysis and compared their consistency with mortality outcomes. Methods: Studies were identified from the PubMed and Embase databases from January 1994 to July 2011 by cross-referencing the following MeSH terms: 'thrombolysis', 'recombinant tissue plasminogen activator', 'rtPA', 'hemorrhagic stroke', 'cerebral hemorrhage', 'hematoma' and 'ischemic stroke'. Demographic information, baseline National Institute of Health Stroke Scale (NIHSS) scores, time from stroke onset to intravenous thrombolysis, SICH and mortality rates were derived from published data in 7 randomized controlled trials, 7 stroke registries and 10 cohort studies (4 multicenter and 6 single center) with more than 200 consecutively recruited patients. Mortality rates were considered as the percentage of patients treated with intravenous thrombolysis who died within 90 days after stroke. Results: The mean age of patients included in this analysis was 68.8 years (standard deviation, SD 2.9, range 63-75), of whom 56.3% (SD 4.5, range 45-63) were men. They presented with a mean baseline NIHSS of 12.5 (SD 1.4, range 9-15) and received intravenous thrombolysis 175 min (SD 62, range 120-328) from stroke onset. The overall mean SICH and mortality rates of patients treated with intravenous thrombolysis were 5.6% (SD 2.3) and 14.7% (SD 4.8), respectively. A moderate correlation was observed between the incidence of SICH and mortality in patients treated with intravenous thrombolysis (r = 0.401, p = 0.050). The variation in SICH rates was highest across studies that reported SICH rates using the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria compared with the European Cooperative Acute Stroke Study and National Institute of Neurological Disorders and Stroke (NINDS) criteria. Studies that defined SICH as parenchymal hemorrhage with a neurological decline NIHSS >= 4 occurring within 36 h of intravenous thrombolysis reported a higher consistency between SICH and mortality rates (correlation coefficient 0.631). Conclusions: SICH rates vary considerably between studies and these differences may relate to the differences in the criteria used to define SICH. Until a case definition with high inter-rater agreement and good correlation with stroke outcomes becomes available, detailed information on the type of bleeding, the extent of NIHSS deterioration, neuroimaging features and the time from thrombolysis to diagnosis of hemorrhage should be reported to permit a correct interpretation of SICH rates. Copyright (c) 2012 S. Karger AG, Basel
引用
收藏
页码:106 / 114
页数:9
相关论文
共 35 条
  • [1] Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR
    Ahmed, Niaz
    Wahlgren, Nils
    Grond, Martin
    Hennerici, Michael
    Lees, Kennedy R.
    Mikulik, Robert
    Parsons, Mark
    Roine, Risto O.
    Toni, Danilo
    Ringleb, Peter
    [J]. LANCET NEUROLOGY, 2010, 9 (09) : 866 - 874
  • [2] Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study
    Albers, Gregory W.
    Thijs, Vincent N.
    Wechsle, Lawrence
    Kemp, Stephanie
    Schlaug, Gottfried
    Skalabrin, Elaine
    Bammer, Roland
    Kakuda, Wataru
    Lansberg, Maarten G.
    Shuaib, Ashfaq
    Coplin, William
    Hamilton, Scott
    Moseley, Michael
    Marks, Michael P.
    [J]. ANNALS OF NEUROLOGY, 2006, 60 (05) : 508 - 517
  • [3] Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study
    Albers, GW
    Bates, VE
    Clark, WM
    Bell, R
    Verro, P
    Hamilton, SA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09): : 1145 - 1150
  • [4] Hemorrhagic transformation of ischemic brain tissue -: Asymptomatic or symptomatic?
    Berger, C
    Fiorelli, M
    Steiner, T
    Schäbitz, WR
    Bozzao, L
    Bluhmki, E
    Hacke, W
    von Kummer, R
    [J]. STROKE, 2001, 32 (06) : 1330 - 1335
  • [5] Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (≥80 years) stroke patients
    Berrouschot, J
    Röther, J
    Glahn, J
    Kucinski, T
    Fiehler, J
    Thomalla, G
    [J]. STROKE, 2005, 36 (11) : 2421 - 2425
  • [6] Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese Patients The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study
    Chao, A-Ching
    Hsu, Hung-Yi
    Chung, Chih-Ping
    Liu, Chung-Hsiang
    Chen, Chih-Hung
    Teng, Michael Mu-Huo
    Peng, Giia-Sheun
    Sheng, Wen-Yung
    Hu, Han Hwa
    [J]. STROKE, 2010, 41 (05) : 885 - 890
  • [7] Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial
    Clark, WM
    Wissman, S
    Albers, GW
    Jhamandas, JH
    Madden, KP
    Hamilton, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2019 - 2026
  • [8] Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial
    Davis, Stephen M.
    Donnan, Geoffrey A.
    Parsons, Mark W.
    Levi, Christopher
    Butcher, Kenneth S.
    Peeters, Andre
    Barber, P. Alan
    Bladin, Christopher
    De Silva, Deidre A.
    Byrnes, Graham
    Chalk, Jonathan B.
    Fink, John N.
    Kimber, Thomas E.
    Schultz, David
    Hand, Peter J.
    Frayne, Judith
    Hankey, Graeme
    Muir, Keith
    Gerraty, Richard
    Tress, Brian M.
    Desmond, Patricia M.
    [J]. LANCET NEUROLOGY, 2008, 7 (04) : 299 - 309
  • [9] Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update
    Derex, L.
    Nighoghossian, N.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 (10) : 1093 - 1099
  • [10] Asymptomatic hemorrhage after thrombolysis may not be benign - Prognosis by hemorrhage type in the Canadian Alteplase for Stroke Effectiveness Study registry
    Dzialowski, Imanuel
    Pexman, J. H. Warwick
    Barber, Philip A.
    Demchuk, Andrew M.
    Buchan, Alastair M.
    Hill, Michael D.
    [J]. STROKE, 2007, 38 (01) : 75 - 79